Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd raised its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 2.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 83,297 shares of the company’s stock after purchasing an additional 1,995 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Syndax Pharmaceuticals were worth $1,101,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of SNDX. State Street Corp increased its stake in shares of Syndax Pharmaceuticals by 4.1% during the third quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after buying an additional 148,491 shares during the period. Assenagon Asset Management S.A. grew its holdings in Syndax Pharmaceuticals by 343.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock worth $27,292,000 after acquiring an additional 1,598,428 shares in the last quarter. Geode Capital Management LLC grew its holdings in Syndax Pharmaceuticals by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock worth $38,066,000 after acquiring an additional 66,459 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after purchasing an additional 208,043 shares during the last quarter. Finally, First Turn Management LLC raised its holdings in shares of Syndax Pharmaceuticals by 85.4% in the 3rd quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after purchasing an additional 546,776 shares in the last quarter.

Insiders Place Their Bets

In other news, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Neil Gallagher sold 4,618 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,683 shares of company stock valued at $336,087. Insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Trading Up 2.2 %

Shares of SNDX opened at $15.57 on Thursday. The company’s 50 day simple moving average is $14.04 and its 200-day simple moving average is $16.87. Syndax Pharmaceuticals, Inc. has a 12-month low of $12.06 and a 12-month high of $25.34. The firm has a market cap of $1.33 billion, a PE ratio of -4.29 and a beta of 0.90.

Wall Street Analyst Weigh In

SNDX has been the subject of a number of analyst reports. Citigroup boosted their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. Scotiabank cut their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. JPMorgan Chase & Co. upped their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group raised their price objective on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).